×
About 3,585 results

ALLMedicine™ Immune Thrombocytopenia Center

Research & Reviews  1,243 results

Atorvastatin restores imbalance of cluster of differentiation 4 (CD4)+ T cells in immun...
https://doi.org/10.1111/bjh.17938
British Journal of Haematology; Xu P, Zhao Y et. al.

Nov 27th, 2021 - Immune thrombocytopenia (ITP) is an autoimmune haemorrhagic disease, in which the overactivation of T cells is crucial in the pathogenesis. Atorvastatin (AT), a lipid-lowering medicine, has shown promising immunomodulatory effects in certain infla...

Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for ...
https://doi.org/10.1111/jth.15602
Journal of Thrombosis and Haemostasis : JTH; Mei H, Liu X et. al.

Nov 26th, 2021 - The efficacy of hetrombopag in Chinese patients with immune thrombocytopenia (ITP) has been demonstrated in a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT03222843). This study aimed to report comprehensive data o...

The structure, function, and clinical use of the thrombopoietin receptor agonist avatro...
https://doi.org/10.1016/j.blre.2021.100909
Blood Reviews; Kuter DJ

Nov 25th, 2021 - Thrombopoietin regulates platelet production through activation of the thrombopoietin receptor (TPO-R). TPO-R agonists (TPO-RAs) are available to treat thrombocytopenia in chronic immune thrombocytopenia (ITP), chronic liver disease (CLD) patients...

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
https://clinicaltrials.gov/ct2/show/NCT04669600

Nov 25th, 2021 - Study duration: Screening period: up to 56 days Transition period between last sutimlimab dose and first dose of BIVV020 (for participants who were previously receiving sutimlimab): 14 days, included as part of the 56-day Screening period Treatmen...

Attention all anti-vaccinators: The cutaneous adverse events from the mRNA COVID-19 vac...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139532
Clinics in Dermatology; Gronbeck C, Grant-Kels JM

Nov 24th, 2021 - Despite the growing availability of coronavirus disease 2019 (COVID-19) vaccines in the general population, a significant proportion of individuals demonstrate vaccine hesitancy. We sought to consolidate and update current evidence on cutaneous ad...

see more →

Guidelines  4 results

American Society of Hematology 2019 guidelines for immune thrombocytopenia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963252
Blood Advances; Neunert C, Terrell DR et. al.

Dec 4th, 2019 - Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients. These evidence-based guidelines of t...

The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocy...
https://doi.org/10.1111/bjh.15735
British Journal of Haematology; Hill QA, Grainger JD et. al.

Jan 5th, 2019 - The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper.|2019|Hill QA,Grainger JD,Thachil J,Provan D,Evans G,|adverse effects,therapeu...

The American Society of Hematology 2011 evidence-based practice guideline for immune th...
https://doi.org/10.1182/blood-2010-08-302984
Blood Neunert C, Lim W et. al.

Feb 18th, 2011 - Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the American Society of Hematology published a landmark guidance paper designed to assist clinicians in the management of this disorder. Since 1996 there have been...

International consensus report on the investigation and management of primary immune th...
https://doi.org/10.1182/blood-2009-06-225565
Blood Provan D, Stasi R et. al.

Oct 23rd, 2009 - Previously published guidelines for the diagnosis and management of primary immune thrombocytopenia (ITP) require updating largely due to the introduction of new classes of therapeutic agents, and a greater understanding of the disease pathophysio...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  63 results

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
https://clinicaltrials.gov/ct2/show/NCT04669600

Nov 25th, 2021 - Study duration: Screening period: up to 56 days Transition period between last sutimlimab dose and first dose of BIVV020 (for participants who were previously receiving sutimlimab): 14 days, included as part of the 56-day Screening period Treatmen...

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
https://clinicaltrials.gov/ct2/show/NCT04224688

Nov 19th, 2021 - The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
https://clinicaltrials.gov/ct2/show/NCT05086744

Nov 11th, 2021 - The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

Prediction Model for Critical ITP Bleeds in Primary Immune Thrombocytopenia Inpatients
https://clinicaltrials.gov/ct2/show/NCT05116423

Nov 11th, 2021 - Primary immune thrombocytopenia (ITP) is a common acquired autoimmune disease characterized by reduced platelet production and increased platelet destruction due to autoimmune disorders, as patients present with low platelet counts and a high risk...

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
https://clinicaltrials.gov/ct2/show/NCT04225156

Nov 8th, 2021 - This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.

see more →

News  104 results

Spreading Newfound Treatment Strategies in Hematologic Malignancies in Seattle
https://www.onclive.com/view/spreading-newfound-treatment-strategies-in-hematologic-malignancies-in-seattle

Oct 6th, 2021 - We recently traveled to Seattle, California for an OncLive® State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from Seattle Cancer Care Alliance provided insight on current and evolving standards of care in leukemia,...

EU Finds J&J COVID Shot Possibly Linked to Another Rare Clotting Condition
https://www.medscape.com/viewarticle/960086

Oct 4th, 2021 - (Reuters) - The European Union's drug regulator on Friday identified a possible link between rare cases of venous thromboembolism with Johnson & Johnson's COVID-19 vaccine and recommended the condition be listed as a side-effect of the shot. The E...

Immunosuppressant-Glucocorticoid Combo Increases Platelets in Immune Thrombocytopenia
https://www.medscape.com/viewarticle/958027

Sep 3rd, 2021 - (Reuters Health) - In patients with immune thrombocytopenia, the immunosuppressant mycophenolate mofetil, when added to a glucocorticoid, can increase platelet counts and reduce the number of treatment failures compared with glucocorticoid therapy...

UK COVID-19 Update: NHS Treatment Figures, Blood Clots After AZ Vaccine Analysis
https://www.medscape.com/viewarticle/956119

Aug 12th, 2021 - These are the UK coronavirus stories you need to know about today. NHS Recovery The NHS said it was continuing to make progress on non-urgent care despite experiencing one of its busiest summers ever. It released figures showing that the number of...

Two Flags for Poor Prognosis After Rare VITT With AstraZeneca Jab
https://www.medscape.com/viewarticle/956478

Aug 12th, 2021 - British doctors have identified two factors — very low platelet counts and brain bleeds — which they say dramatically increase the likelihood of a patient dying following the very rare but devastating side effect of vaccine-induced immune thromboc...

see more →

Patient Education  5 results see all →